Ligand stimulation of PDGF ␤-receptors leads to autophosphorylation of the regulatory tyrosine 857 and of tyrosine residues that in their phosphorylated form serve as docking sites for Src homology 2 domain-containing proteins. Regulation of the PDGF ␤-receptor by protein-tyrosine phosphatases is poorly understood. We have investigated PDGF ␤-receptor dephosphorylation by receptor-like protein-tyrosine phosphatase DEP-1 using a cell line with inducible DEP-1 expression and by characterizing in vitro dephosphorylation of the PDGF ␤-receptor and of receptor-derived phosphopeptides by DEP-1. After DEP-1 induction PDGF ␤-receptor⅐DEP-1 complexes and reduced receptor tyrosine phosphorylation were observed. Phosphopeptide analysis of the PDGF ␤-receptors from DEP-1-expressing cells and of the receptors dephosphorylated in vitro by DEP-1 demonstrated that dephosphorylation of autophosphorylation sites of the receptor differed and revealed that the regulatory Tyr(P) 857 was not a preferred site for DEP-1 dephosphorylation. When dephosphorylation of synthetic receptor-derived peptides was analyzed, the selectivity was reproduced, indicating that amino acid sequence surrounding the phosphorylation sites is the major determinant of selectivity. This notion is supported by the observation that the poorly dephosphorylated Tyr(P) 562 and Tyr(P) 857 , in contrast to other analyzed phosphorylation sites, are surrounded by basic amino acid residues at positions ؊4 and ؉3 relative to the tyrosine residue. Our study demonstrates that DEP-1 dephosphorylation of the PDGF ␤-receptor is site-selective and may lead to modulation, rather than general attenuation, of signaling.
Receptor tyrosine kinases (RTKs) 1 transmit extracellular signals and regulate multiple cellular processes including proliferation, motility, differentiation, and metabolism. Most RTKs are activated by ligand-induced dimerization, which leads to autophosphorylation (1, 2) . The phosphorylated tyrosine residues are either involved in activation of the intrinsic kinase activity or serve as docking sites for downstream signaling proteins containing phosphotyrosine recognition domains, such as Src homology 2 (SH2) or phosphotyrosine-binding (PTB) domains (3) . Receptor-like protein-tyrosine phosphatases (rPTPs) are a family of enzymes composed of structurally variable extracellular domains, a single transmembrane segment, and one or two intracellular catalytic PTP domains (4, 5) . The notion that rPTPs act as negative regulators of RTK signaling by direct dephosphorylation of RTKs has received some experimental support. For example, overexpression of CD45 reduces PDGF receptor tyrosine phosphorylation (6) , and antisense-mediated suppression of LAR potentiates signaling of various growth factor receptors, including insulin and EGF receptors (7, 8) . Also, data for negative regulation of EGF receptor signaling by rPTP in A431 cells have been obtained by inducible overexpression of rPTP and by down-regulation of endogenous rPTP expression levels with an antisense approach (9) . Genetic screening in Caenorhabditis elegans recently identified an rPTP, CLR-1, as a negative regulator of signaling through the C. elegans fibroblast growth factor receptor homologue EGL-15 (10) . It is largely unknown whether rPTP-mediated RTK dephosphorylation leads to general attenuation of RTK signaling by targeting of the regulatory phosphotyrosine or by general dephosphorylation or rather modulates signaling through site-selective dephosphorylation.
The signaling mechanism of the PDGF ␤-receptor, an RTK expressed predominantly in fibroblasts and smooth muscle cells, has been extensively characterized (11) . Binding of the ligand, PDGF-BB, leads to receptor dimerization and autophosphorylation of multiple tyrosine residues. One of the autophosphorylation sites of the PDGF ␤-receptor, Tyr 857 , located in the kinase domain, regulates the catalytic activity of the kinase (12, 13) . 11 of the 15 tyrosine residues outside the catalytic domain have been demonstrated to undergo autophosphorylation after ligand stimulation. For some of the autophosphorylation sites, the SH2 domain-containing signaling proteins that bind to the site are identified, for example Tyr(P) 740 and Tyr(P) 751 in the kinase insert region bind the regulatory p85 subunit of phosphatidylinositide 3Ј-kinase (14) , Tyr(P) 1021 and Tyr (P) 1009 bind phospholipase C␥1 with high and low affinity, respectively (15) , and Tyr(P) 1009 binds SHP-2 (29, 30) . DEP-1 (density-enhanced phosphatase-1), also designated PTP-and CD148, is an rPTP structurally composed of an extracellular domain containing eight type III fibronectin repeats, a transmembrane segment, and a single intracellular catalytic domain (16, 17) . The expression pattern of DEP-1 is not fully characterized, but expression has been demonstrated in hematopoietic cells, fibroblasts, and endothelial cells (17) (18) (19) . DEP-1 negatively regulates TCR-mediated activation of T-cells (20, 21) . The function of DEP-1 in fibroblasts is less clear, but the increased expression of DEP-1 at high cell density suggests an involvement in contact inhibition of cell growth (17) .
This study was performed to investigate the possibility that PDGF ␤-receptor is a substrate for DEP-1 and, if so, whether dephosphorylation leads to a general decrease in phosphotyrosine content of the PDGF ␤-receptor or rather results in dephosphorylation of specific SH2 domain-binding phosphorylation sites. We demonstrate dephosphorylation of the PDGF ␤-receptor in vivo after DEP-1 induction, as well as physical association between DEP-1 and PDGF ␤-receptor. Analyses of in vitro and in vivo DEP-1 dephosphorylation of the PDGF ␤-receptor, as well as of PDGF ␤-receptor-derived synthetic peptides revealed site-selective dephosphorylation, predominantly determined by the primary sequence surrounding the phosphorylation site. The regulatory Tyr(P) 857 was not a preferred site for dephosphorylation.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents-Mouse monoclonal antibody 143.41 recognizing the extracellular domain of DEP-1 (19) , mouse monoclonal antibodies B1 and B2 recognizing different epitopes within the extracellular domain of the PDGF ␤-receptor (22) , PDGF ␤-receptor rabbit polyclonal antiserum R3 recognizing the carboxyl-terminal domain of the PDGF ␤-receptor (23), as well as rabbit HA tag antiserum (24) have been described earlier. Mouse monoclonal phosphotyrosine antibody, PY99, was from Santa Cruz Biotechnology (Santa Cruz, CA). VSV-G monoclonal antibody was purchased from Sigma. Rabbit anti-mouse IgG were from Dako (Glostrup, Denmark). Human recombinant PDGF-BB was from Amgen (Thousand Oaks, CA). Isopropyl-␤-D-galactopyranoside and hygromycin B were bought from Calbiochem (La Jolla, CA), anhydrotetracycline (Atc) was from Acros Organics (Geel, Belgium), and Geneticin (G418) was from Life Technologies, Inc. Hybond C-extra nitrocellulose membranes, sheep anti-mouse and donkey anti-rabbit horseradish peroxidase-conjugated Ig, ECL Western blotting detection reagents, [ Plasmids-The components of the tetracyline-regulated ("tet-minus") expression system, pUHD10-3 and pUHD15-1, (25) were kindly provided by Dr. H. Bujard (Zentrum fü r Molekulare Biologie, Heidelberg, Germany). The DEP-1 cDNA was excised with EcoRI from the previously described plasmid pSV7d-DEP1 (17) and subcloned into EcoRI-linearized and dephosphorylated pUHD10-3. Introduction of a sequence for the VSV-G tag into DEP-1 cDNA was performed as described earlier (26) , resulting in the plasmid pUHD10-3DEP-1vsv. Carboxyl-terminal HA tag was introduced into human PDGF ␤-receptor cDNA in the following way: the plasmid pcDNA3-PDGF␤R was digested with KpnI/EcoRI and filled with T4 polymerase to remove KpnI, BamHI, and EcoRI. The carboxyl-terminal 600 base pairs of the PDGF ␤-receptor cDNA were amplified by PCR using the primers PDGF1A (5Ј-GTGGATGGCTCCGGAGAG-3Ј) and PDGF1B (5Ј-GTGCATTCTA-GAGCTGGGTACCTATCCTCTGCTTC-3Ј). The primer PDGF1B introduced a KpnI site preceding the stop codon and an XbaI site after the stop codon. This fragment was used to generate the plasmid pcDNA3-PDGF␤RKX. The fragment containing three repeats of the HA epitope followed by a stop codon was cut out from the plasmid pBSKS-HATAGA with KpnI and XbaI and cloned into the vector pcDNA3-PDGF␤RKX opened with the same enzymes resulting in pcDNA3-PDGF␤R-HA. The plasmid expressing the hygromycin resistance gene (pSB2hyg) was generously provided by Dr. Thomas Beckers (Tumor Research, ASTA Medica AG, Frankfurt/M., Germany). The expression plasmid pGEX-3X/DEP-1ic was generated by cloning a 1133-base pair EcoRI/EcoRI PCR fragment of HA-tagged human DEP-1 cDNA into pGEX-3X bacterial expression vector (Amersham Pharmacia Biotech). The plasmid encodes a fusion protein with an amino-terminal GST domain and amino acids 997-1337 of DEP-1 followed by a triple repeat of the HA epitope.
Cell Culture and Transfections-Porcine aortic endothelial cells stably expressing human PDGF ␤-receptor (PAE/PDGFR-␤; Ref. 27 ) were cultured in a 1:1 mixture of Dulbecco's modified Eagle's medium/Ham's F-12 medium supplemented with 10% fetal calf serum, 4500 mg/liter glucose, 2 mM glutamine, 1000 units/liter penicillin, 1 mg/liter streptomycin, and 400 mg/liter G418 at 37°C in humidified atmosphere containing 5% CO 2 , 95% air. PAE/PDGFR-␤ cells were cotransfected with three plasmids: pUHD15-1, encoding the tetracycline-responsive transcriptional activator; pSB2hyg, carrying the hygromycin resistance gene; and pUHD10-3DEP1vsv, encoding VSV-G-tagged human DEP-1. The transfection was carried out with SuperFect according to the instructions of the supplier (QIAGEN GmbH, Hilden, Germany) with minor modifications. Briefly, 1 day before transfection 4 ϫ 10 5 cells were plated per 100-mm tissue culture dish. The vectors pUHD15-1, pUHD10-3DEP1vsv, and pSB2hyg were linearized, and DNA amounts of 3, 3, and 0.6 g, respectively, were mixed with 300 l of Dulbecco's modified Eagle's medium/Ham's F-12, and 60 l of SuperFect were added to the mixture. This transfection complex solution was combined with 3 ml of medium and transferred to the cells. After 3.5 h of incubation, the solution was aspirated, and the cells were rinsed three times with serum-free Dulbecco's modified Eagle's medium/Ham's F-12 medium. Subsequently, cell growth medium containing fetal calf serum was added to the cells. 100 g/ml hygromycin and 100 ng/ml Atc were added to the cells 24 h after transfection. After 3 days the hygromycin concentration was increased to 200 g/ml. Atc was present throughout selection. For screening of DEP-1-expressing cell clones, cells were grown in the absence of Atc for 5 days. To suppress DEP-1 expression in these cells, Atc was added to culture medium when the cells were seeded for experiment (3 days before harvesting).
PDGF-BB Stimulation, Immunoprecipitations, and Immunoblotting-Cells were grown to subconfluence in the absence or presence of 100 ng/ml Atc and incubated overnight in serum-free medium, also with or without Atc. The cells were then left unstimulated or stimulated with 100 ng/ml PDGF-BB for 5 min at 37°C, washed twice with ice-cold PBS containing 0.25 mM sodium orthovanadate, and lysed in lysis buffer A containing 0.5% Triton X-100, 0.5% sodium deoxycholate, 20 mM TrisHCl, pH 7.5, 150 mM NaCl, 10 mM EDTA, 30 mM Na 2 P 2 O 7 , 1% Trasylol, 1 mM phenylmethylsulfonyl fluoride, and 0.25 mM sodium orthovanadate. Lysates were clarified by centrifugation. Immunoprecipitations were done in aliquots of lysates derived from equal numbers of cells (cells were counted in parallel cultures). PDGF ␤-receptor was immunoprecipitated with a mixture of B1 and B2 monoclonal antibodies followed by rabbit anti-mouse IgG or with R3 antiserum. DEP-1 was immunoprecipitated using 143.41 mouse monoclonal antibodies and rabbit anti-mouse IgG. Immunocomplexes were collected on Immunosorb A (Medicago, Uppsala, Sweden), washed four times with lysis buffer A, washed once with 40 mM HEPES, pH 7.4, and resolved by SDS-PAGE. Proteins were transferred from gel to Hybond C-extra nitrocellulose membranes and subjected to immunoblotting. Detection was done using sheep anti-mouse or donkey anti-rabbit horseradish peroxidase-conjugated Ig and ECL reagents.
PDGF-BB Binding Assay-PDGF-BB was labeled according to Bolton and Hunter (31) . X23 cells were grown in 24-well plates to confluence, rinsed once with binding buffer (PBS containing 1 mg/ml bovine serum albumin, 0.068 mM CaCl 2 and 0.05 mM MgCl 2 ), and incubated for 2 h on ice in 0.5 ml binding buffer containing 1 ng/ml of 125 I-labeled PDGF-BB and various concentrations of unlabeled PDGF-BB. After that, cells were washed five times with ice-cold binding buffer and lysed in 0.5 ml of 1% Triton X-100, 20 mM HEPES, pH 7.4, and 10% glycerol, and cell-associated radioactivity was quantified in a ␥-counter. Cell numbers were counted using parallel cultures.
Expression and Purification of GST-DEP-1 Intracellular Domain (GST-DEP-1ic)-GST-DEP-1ic
fusion protein was expressed in JM101 strain of Escherichia coli. Expression was induced by the addition of 0.5 mM isopropyl-␤-D-galactopyranoside to 400 ml of log-phase culture, and bacteria were harvested by centrifugation after 5 h of culture at 30°C. Bacterial pellet was lysed in 10 ml of PBS containing 1% Triton X-100, 2 mM EDTA, 10 mM DTT, and 0.2 mM phenylmethylsulfonyl fluoride for 20 min on ice and sonicated (five 30-s pulses at 10% full capacity, UW 2200 sonifier from Bandelin Electronic, Berlin, Germany). The lysate was centrifuged for 10 min at 11,000 ϫ g, and supernatant was incubated with 1 ml of 50% slurry of glutathione-Sepharose (Amersham Pharmacia Biotech) by slow rotation for 1 h at 4°C. The beads were collected by centrifugation and washed five times with the lysis buffer. GST-DEP-1ic was eluted with 2 ml of 50 mM Tris-HCl, pH 8.0, containing 20 mM glutathione, dialyzed against 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM DTT, and stored at 4°C. No considerable loss of activity was observed within 2 weeks of storage. Exact concentration of GST/ DEP-1ic in the preparation was determined by quantitative amino acid analysis of the recombinant protein band excised from the gel after SDS-PAGE.
Preparation of in Vitro Phosphorylated PDGF ␤-Receptor-COS7 cells were transiently transfected with the pcDNA3-PDGF␤R-HA plasmid. 48 h after transfection, cells were washed twice with ice-cold PBS and stimulated with 100 ng/ml PDGF-BB in binding buffer for 1 h on ice. The cells were lysed in lysis buffer A, lysates were clarified by centrifugation, and HA-tagged PDGF ␤-receptor was immunoprecipitated with HA tag antiserum for 1 h at 4°C. Immunocomplexes were collected on Immunosorb A beads, washed four times with lysis buffer A and twice with kinase assay buffer (20 mM HEPES, pH 7.5, 10 mM MnCl 2 , 1 mM DTT, 0.05% Triton X-100, 0.1 mM sodium orthovanadate).
Immunoprecipitates were suspended in the kinase assay buffer, and autophosphorylation reaction was performed in the presence of 50 Ci of [␥- 32 P]ATP for 20 min on ice. The reaction was stopped by the addition of N-ethylmaleimide to 10 mM final concentration, and the beads were washed three times with lysis buffer A containing 0.5 M NaCl.
In Vitro Dephosphorylation of the PDGF ␤-Receptor-Aliquots of Immunosorb A-immobilized autophosphorylated PDGF ␤-receptor from approximately 1.5 ϫ 10 6 transfected COS7 cells were suspended in 40 l of buffer containing 20 mM imidazole, pH 7.5, 0.05% Triton X-100, 10 mM DTT, 0.1 mg/ml bovine serum albumin, and incubated with different amounts of purified GST-DEP-1ic for 30 min at 30°C. Total reaction volume was 60 l. Dephosphorylation was terminated by the addition of SDS-PAGE sample buffer, and PDGF ␤-receptor was separated by SDS-PAGE, transferred to Hybond C-extra nitrocellulose membrane and visualized by autoradiography.
Labeling of Cells with [ 32 P]
Orthophosphate-X23 cells were grown to subconfluence in the absence or presence of Atc and starved overnight in serum-free medium, also with or without Atc. The cells were then washed four times with phosphate-free HEPES-buffered Ham's F-12 medium and incubated in the same medium containing 1.5 mCi/ml [ 32 P]orthophosphate for 4 h at 37°C. Labeling was done in the absence of any PTP inhibitors, and 100 ng/ml Atc was added for the period of labeling, where necessary. After 4 h, the cells were stimulated for 5 min at 37°C with 100 ng/ml PDGF-BB added to the labeling medium, washed three times with ice-cold PBS containing 0.5 mM sodium orthovanadate and lysed in lysis buffer A containing 1 mM sodium orthovanadate. PDGF ␤-receptor was immunoprecipitated with a mixture of B1 and B2 monoclonal antibodies from lysate aliquots containing equal numbers of cells (cells were counted in parallel cultures that were not labeled with [ 32 P]orthophosphate). Two-dimensional Tryptic Phosphopeptide Mapping of the PDGF ␤-Receptor, Phosphoamino Acid Analysis, and Edman DegradationBands of in vitro or in vivo labeled PDGF ␤-receptor were excised from the nitrocellulose membrane and processed as described (28) . Tryptic phosphopeptides were separated on thin layer cellulose plates (Merck, Darmstadt, Germany) by electrophoresis at pH 1.9 (first dimension, 40 min at 2000 V) and ascending chromatography (second dimension, 15 h in isobutyric acid/n-butanol/pyridine/acetic acid/H 2 O, 1250:38:96:58:558, v/v/v/v/v). The resulting maps were exposed on BioImager screens (Fujix BAS 2000 Bio-Image Analyzer, Fuji, Japan), and 32 P content of the phosphopeptides selected for this study was quantified with TINA program as intensities of the corresponding spots on the image. The 32 P content of the whole receptor was quantified as the intensity of the entire image.
Phosphopeptides pY857, pY751, pY1009/pY1021, containing autophosphorylation sites Tyr(P) 857 , Tyr(P) 751 , and Tyr(P) 1009 /Tyr(P) 1021 , respectively, as well as phosphopeptide R4, were identified by their migratory position on two-dimensional phosphopeptide maps, 2 and their identity was confirmed by radiosequencing and phosphoamino acid analysis. Identification of peptide R12 as the peptide containing Tyr(P) 562 is described in detail under "Results." For phosphoamino acid analysis, 32 P-labeled phosphopeptides were scraped off the plates, eluted from cellulose with electrophoresis buffer, pH 1.9, with chromatography buffer, or with 30% formic acid, dried, and hydrolyzed in 6 M HCl for 1 h at 110°C. Phosphoamino acids were separated by two-dimensional electrophoresis on thin layer cellulose plates, as described (28), and visualized by autoradiography. Edman degradation of eluted and dried phosphopeptides was performed as previously described (32) . Phosphopeptide solutions were adjusted to pH 7.5, and the exact concentration of phosphopeptides was determined by quantitative amino acid analysis. Dephosphorylation reaction was started by addition of 2 nM purified GST-DEP-1ic to a quartz cuvette (length ϭ 1 cm) containing 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.15 mM NaCl, 1 mM DTT, and 50 M phosphopeptide prewarmed to 30°C. Total reaction volume was 500 l. Immediately after addition of the enzyme, dephosphorylation was continuously monitored by measuring the increase of optical density at 282 nm (33), using a DU640 spectrophotometer (Beckman, Fullerton, CA) equipped with a temperature-controlled cuvette holder. The relative amount of each phosphopeptide left after 3 min of dephosphorylation was determined.
Synthesis of PDGF ␤-Receptor-derived Phosphopeptides and Their in Vitro Dephosphorylation by GST-DEP-1ic-Four

RESULTS
Induction of DEP-1 Expression Leads to Reduced Tyrosine
Phosphorylation of the PDGF ␤-Receptor-To develop a system in which the effects of DEP-1 expression on PDGF ␤-receptor phosphorylation in vivo could be studied, the previously established PAE/PDGF ␤-receptor cell line (PAE/PDGFR-␤) was supertransfected with constructs encoding the tetracycline-responsive transcriptional activator and a VSV-G-tagged form of human DEP-1 under the control of a tetracycline-responsive transcriptional activator-regulated promoter. A number of clones with regulated expression of DEP-1 were obtained, and one clone (X23) was selected for further characterization (Fig.  1, top panel) PDGF ␤-receptor, as determined by immunoblotting (Fig. 1,  bottom panel) . However, phosphotyrosine immunoblotting revealed that induction of DEP-1 expression reduced tyrosine phosphorylation of ligand-stimulated PDGF ␤-receptor (Fig. 1,  middle panel) . To exclude that this effect was caused by alteration in PDGF-BB binding to the PDGF ␤-receptors, a radio receptor assay using iodinated PDGF-BB was performed. As shown in Fig. 2 , there was no evidence of changes in PDGF-BB binding after induction of DEP-1 expression.
DEP-1 Forms a Physical
Complex with the PDGF ␤-Receptor-Physical complexes between rPTPs and RTKs have previously been demonstrated, e.g. in the case of insulin receptor and LAR (46) . We therefore investigated whether DEP-1 expression in X23 cells leads to formation of DEP-1⅐PDGF ␤-receptor complexes.
The monoclonal antibody 143.41, which recognizes the extracellular domain of DEP-1, was used for DEP-1 immunoprecipitations. After SDS-PAGE and transfer to nitrocellulose membranes, the possible presence of co-immunoprecipitating PDGF ␤-receptor was investigated by anti-PDGF ␤-receptor immunoblotting of DEP-1 immunoprecipitates. As shown in Fig. 3 , PDGF-independent co-immunoprecipitation of DEP-1 and PDGF ␤-receptor was observed. The finding that induction of DEP-1 expression in X23 cells leads to formation of the DEP-1⅐PDGF ␤-receptor complex strongly suggests that reduced phosphotyrosine content of the PDGF ␤-receptor in DEP-1-expressing cells is a consequence of direct dephosphorylation of the PDGF ␤-receptor by DEP-1.
In Vitro Dephosphorylation of the PDGF ␤-Receptor by GST-DEP-1ic Leads to Site-selective Reduction of Tyrosine Phosphorylation-To address the question of whether DEP-1 induction leads to a general decrease in tyrosine phosphorylation of the PDGF ␤-receptor or rather changes the pattern of autophosphorylated sites, in vitro dephosphorylation experiments were performed. In these experiments, PDGF ␤-receptor labeled with radioactive phosphate in an in vitro kinase reaction was dephosphorylated using a purified fusion protein composed of GST and DEP-1 intracellular domain (GST-DEP-1ic) expressed in E. coli. After incubation of in vitro 32 P-labeled PDGF ␤-receptor with various amounts of GST-DEP-1ic, the dephosphorylation of selected autophosphorylation sites, as well as total dephosphorylation of the receptor, was determined by quantitative analysis of receptor-derived phosphopeptides resolved by two-dimensional phosphopeptide mapping (Fig. 4) .
Under conditions where 50% total dephosphorylation occurred, a variation was observed between 10% dephosphorylation of peptide R12, containing the phosphorylation site Tyr(P) 562 (see below), and 70% dephosphorylation of peptide R4, which contains phosphorylation sites Tyr(P) 763 , Tyr(P) 771 , Tyr(P) 775 , and Tyr(P) 778 of the PDGF ␤-receptor kinase insert (Fig. 4C) . Because of the low recovery of R4 after extraction from two-dimensional phosphopeptide maps, we were unable to determine the extent of dephosphorylation for each of the four sites of peptide R4. Phosphopeptides pY857, containing the regulatory Tyr(P) 857 , pY751, containing phosphatidylinositide 3Ј-kinase-binding Tyr(P) 751 , and pY1009/pY1021, containing phospholipase C␥1-and SHP-2-binding Tyr(P) 1009 and Tyr(P) 1021 were also selected for quantification. Among these peptides, pY857 was the least dephosphorylated and pY1009/ pY1021 was the most dephosphorylated (Fig. 4C) . This experiment thus indicates that different phosphorylation sites within the PDGF ␤-receptor vary with regard to susceptibility to DEP-1 dephosphorylation. Furthermore, the regulatory Tyr(P) 857 belongs to the group of least dephosphorylated sites.
Identification of Tyr 562 as an in Vitro Phosphorylation
Site-A phosphopeptide with migratory characteristics similar to those of peptide R12 was observed earlier in two-dimensional phosphopeptide maps of in vitro phosphorylated human PDGF ␤-receptor (47); however, the phosphorylation site it contained has not been identified. The observation that phosphopeptide R12 was an exceptionally poor substrate for GST-DEP-1ic prompted identification of this site. Phosphoamino acid analysis, Edman degradation, and treatment of the phosphopeptide R12 with endoproteinase Asp-N revealed that peptide R12 contained a phosphorylated tyrosine residue at position 1 (Fig.  5A ) and was resistant to Asp-N cleavage. 3 Of all theoretically possible peptides that could be generated by tryptic cleavage of the PDGF ␤-receptor intracellular domain, there are four peptides with a tyrosine residue in position 1, and, among these, only the one containing amino acids 562-565 has no cleavage 3 M. Kovalenko, unpublished results. site for Asp-N (Fig. 5B) . Therefore, it was highly probable that R12 represented peptide 562-565. To finally confirm this possibility, 32 P-labeled R12, extracted from the two-dimensional phosphopeptide map of in vitro autophosphorylated PDGF ␤-receptor, was mixed with 1 g of synthetic phosphorylated peptide 562-565 and subjected to electrophoresis at pH 1.9 on thin layer cellulose plate followed by ascending chromatography (Fig. 5C) . As revealed by ninhydrin staining of the plate and subsequent autoradiography, synthetic phosphopeptide 562-565 co-migrated with 32 P-labeled R12, confirming that the two peptides were identical. Thus, the phosphorylation site of peptide R12 is Tyr(P) 562 of human PDGF ␤-receptor. Quantification of the total amount of radioactivity in peptides from the PDGF ␤-receptor derived from DEP-1-expressing cells and control cells revealed a DEP-1-dependent reduction in total radioactivity by approximately 30% (Fig. 6) . Similar reduction in phosphotyrosine was observed when phosphoamino acid analysis of immunoprecipitated receptor was performed, followed by BioImager-based quantification. 3 Quantification of 32 P content of a selected set of phosphopeptides revealed large variations in DEP-1-dependent reduction of peptide phosphorylation. The reduction ranged from 72% in peptide R4, containing four autophosphorylation sites of the kinase insert region, to 30% dephosphorylation in the case of the peptide containing the regulatory Tyr(P) 857 (Fig. 6 ). The Tyr(P) 751 -and Tyr(P) 1009/1021 -containing peptides were also analyzed. In these cases phosphorylation was reduced by 50 and 60%, respectively (Fig. 6) . No peptide migrating like the Tyr(P) 562 -containing peptide of the in vitro labeled receptor was observed on the peptide map of the in vivo labeled receptor. Phosphoamino acid analysis of the peptides showed that more than 90% of the total 32 P content was contributed by phosphotyrosine. 3 The reduction in 32 P content of the peptides therefore represents predominantly reduction in tyrosine phosphorylation.
DEP-1 Induction Changes Tyrosine Phosphorylation
In conclusion, DEP-1 induction changes PDGF ␤-receptor phosphorylation in a site-selective way. The regulatory Tyr(P) 857 was less affected than most sites, and autophosphorylation sites of peptide R4 were more affected than the Tyr(P) 751 and Tyr(P) 1009 /Tyr(P) 1021 sites. This pattern of selectivity is similar to that obtained by in vitro DEP-1 dephosphorylation of the PDGF ␤-receptor and thus lends further support to the notion that reduced PDGF ␤-receptor tyrosine phosphorylation in DEP-1-expressing cells is a consequence of direct dephosphorylation of the receptor by DEP-1. , and Tyr(P) 778 and phosphopeptide R12 contains autophosphorylation site Tyr(P) 562 . Phosphorylation of the whole PDGF ␤-receptor was quantified as intensity of the entire image within the square. B, 32 P content of indicated phosphopeptides and of the whole receptor (total) expressed as a percentage of the corresponding values for nondephosphorylated receptor and plotted against the amount of GST-DEP-1ic used for dephosphorylation. The graph is representative for five experiments. C, phosphorylation state of selected phosphopeptides when 32 P content of the whole receptor (total) is reduced by 50% (values were derived from five graphs of the type that is exemplified in B). Shown are the means Ϯ S.D. for five experiments.
DEP-1 Site Selectivity Is
selectivity was determined by primary amino acid sequence surrounding the analyzed autophosphorylation sites or rather required the structural context provided by the native PDGF ␤-receptor, phosphorylated peptides encompassing the sequences surrounding Tyr(P) 857 , Tyr(P) 751 , Tyr(P)
1021
, and Tyr(P) 562 , as well as the four phosphorylation sites of peptide R4, were synthesized and analyzed as substrates for GST-DEP1ic.
The peptides were incubated at a concentration of 50 M with 2 nM of GST-DEP-1ic, and the extent of dephosphorylation after 3 min incubation at 30°C was determined. As shown in Fig. 7 , dephosphorylation of the selected phosphotyrosines presented in a peptide context occurred with similar relative efficiency as in the intact protein. Whereas 80% dephosphorylation of Tyr(P) 1021 was observed after 3 min, Tyr(P) 562 and Tyr(P) 857 were only dephosphorylated by 10 and 15%, respectively. In vitro dephosphorylation of synthetic PDGF ␤-receptorderived phosphopeptides, each containing one of the phosphorylation sites of peptide R4, showed preference of GST-DEP-1ic for Tyr(P) 771 and Tyr(P) 778 . 3 The extent of dephosphorylation of these was similar to that of the Tyr(P) 1021 -containing peptide, whereas Tyr(P) 763 and Tyr(P) 775 were dephosphorylated with approximately the same efficiency as Tyr(P) 751 . We thus conclude that the site selectivity that DEP-1 displays in PDGF ␤-receptor dephosphorylation is predominantly determined by the primary amino acid sequence surrounding the autophosphorylation sites. DISCUSSION We have studied in detail the dephosphorylation of the PDGF ␤-receptor by DEP-1. We demonstrate physical interaction between the two proteins in vivo. By analyzing reduction in tyrosine phosphorylation of the PDGF ␤-receptor after in vivo and in vitro exposure to DEP-1, evidence for site selectivity in the dephosphorylation reaction is provided. Based on experiments with synthetic phosphopeptides, we conclude that site selectivity is determined predominantly by the primary amino acid sequence around phosphotyrosines.
Evidence that this particular RTK-rPTP pair is physiologically relevant remains to be obtained. However, the reduction in PDGF ␤-receptor tyrosine phosphorylation that was seen in X23 cells after DEP-1 induction was not accompanied by a general decrease in tyrosine phosphorylation of cellular proteins as determined by immunoblotting of whole cell lysates. After lysis, PDGF ␤-receptor was immunoprecipitated from equal numbers of DEP-1-expressing and nonexpressing cells with a mixture of B1 and B2 PDGF ␤-receptor monoclonal antibodies and subjected to tryptic digestion followed by two-dimensional phosphopeptide mapping. 32 P content of selected phosphopeptides and of the whole receptor was quantified with the BioImager. Phosphorylation of peptides containing Tyr(P) 857 , Tyr(P) 751 , and Tyr(P) 1009 /Tyr(P) 1021 and of the peptide R4, containing Tyr(P) 763 , Tyr(P) 771 , Tyr(P) 775 , and Tyr(P) DEP-1 immunoprecipitation followed by anti-PDGF ␤-receptor immunoblotting demonstrated physical interaction between DEP-1 and PDGF ␤-receptor. Physical association has previously been reported for another RTK-rPTP pair, the insulin receptor and LAR (46) . In contrast to what was observed in the case of the insulin receptor-LAR interaction, the association between the PDGF ␤-receptor and DEP-1 was not enhanced by ligand-induced activation of the receptor (Fig. 3) . This suggests that the interaction might involve structures outside the catalytic domain of DEP-1.
Precedent for phosphorylation-independent interactions between PTPs and their substrates exists. An interaction between the SH3 domain of p130cas and the proline-rich region of PTP-PEST has been demonstrated to contribute to the striking substrate specificity of PTP-PEST (35) . Also, a 16-amino acid sequence denoted kinase interaction motif located outside of the PTP-SL catalytic domain, mediates interaction with ERK1/2 (36). In the case of the PDGF ␤-receptor-DEP-1 interactions, structural determinants remain unknown, but analysis of deletion variants of the two proteins is likely to reveal the structural basis for physical interaction.
There is accumulating experimental evidence that RTK signaling is affected by rPTPs. For example, CD45 overexpression negatively regulates insulin-like growth factor-I receptor, insulin receptor, and PDGF ␤-receptor signaling (6, 7), and overexpression of PTP␣ or PTP⑀ reduces insulin receptor signaling (37) . Furthermore, antisense-mediated blockage of LAR expression leads to increased ligand-induced tyrosine phosphorylation of the receptors for insulin, EGF, and hepatocyte growth factor (8, 38) . Finally, in A431 cells rPTP has been shown to negatively regulate EGF receptor signaling (9) .
RPTP dephosphorylation of RTKs can in principle lead to two outcomes: either complete abrogation of the signal through dephosphorylation of the regulatory tyrosine or through general dephosphorylation or, alternatively, selective modulation of the signal output by dephosphorylation of a subset of SH2 domain-or PTB domain-binding phosphotyrosines. Which of these outcomes dominates has not been analyzed in previous studies of RTK-rPTP interactions.
Our demonstration of preferential rPTP dephosphorylation of some of the autophosphorylation sites in an RTK, in vivo and in vitro thus represent a novel finding. The identification of the regulatory Tyr(P) 857 of the PDGF ␤-receptor as a site that is poorly dephosphorylated by DEP-1 raises the intriguing possibility that rPTPs in general might not act to turn off RTK signaling but rather to modulate signaling output. Earlier studies characterizing interactions of cytosolic PTPs with the PDGF ␤-receptor also indicate that dephosphorylation of the PDGF receptor would lead not to a general reduction in phosphotyrosine but rather to selective decrease in the phosphorylation of some sites. For example, overexpression of LMW-PTP drastically reduced recruitment of c-Src to the receptor without affecting the amount of phospholipase C␥1 that associated with the receptor (39) . Also, characterization of in vitro dephosphorylation of the PDGF ␤-receptor by SHP-2 revealed preferential dephosphorylation of Tyr(P) 771 , Tyr(P) 751 , and Tyr(P) 740 (40) . Site-selective dephosphorylation of non-RTK substrates of PTPs might also occur as exemplified by the observation that association of a substrate-trapping mutant form of T-cell phosphatase with Shc is unaffected by mutation of the Tyr 317 phosphorylation site of Shc but strongly reduced by mutation of the Tyr 239 phosphorylation site (41) . Although site selectivity of the PDGF ␤-receptor dephosphorylation was similar in vitro and in vivo, the selectivity was more clear in the in vitro experiment. The most likely explanation for this is that DEP-1 dephosphorylation of the PDGF ␤-receptor in vivo is occurring in a context where also other PTPs, with different or no selectivity, may be acting on the receptor and thereby partially concealing the DEP-1 effect. In association with the in vitro dephosphorylation experiments a novel in vitro tyrosine phosphorylation site, Tyr(P) 562 , was identified as an unpreferred site for DEP-1 dephosphorylation. The absence of the corresponding peptide in the two-dimensional phosphopeptide maps from the in vivo labeled receptor could be caused either by its rapid dephosphorylation by an endogenous PTP in X23 cells or reflect that this site is not an in vivo phosphorylation site. Because this peptide was not recovered from in vivo labeled receptors from cells treated with PTP inhibitors, 2 we favor the hypothesis that this site is not an in vivo phosphorylation site.
Experiments using PDGF ␤-receptor-derived peptides as substrates for GST-DEP-1ic indicated that the site selectivity observed with the intact PDGF ␤-receptor was predominantly determined by the surrounding primary amino acid sequence rather than the structural context of the native receptor. Therefore, it is possible that dephosphorylation susceptibility of a particular phosphotyrosine might be affected by the phosphorylation status of neighboring tyrosine residue(s) (e.g. Tyr(P) 771 , Tyr(P) 775 , and Tyr(P) 778 in the kinase insert of the PDGF ␤-receptor). Interestingly, the poorly dephosphorylated Tyr(P) 562 and Tyr(P) 857 display some similarities in that both have basic amino acid residues at position Ϫ4 and ϩ3 relative to the phosphotyrosine. The finding that the amino acid sequence surrounding the phosphorylation site represents the major determinant for specificity is in agreement with biochemical studies. In an investigation of the specificity of the Yersinia PTP, a close to 100-fold difference in K m was observed when a panel of alanine scan peptides based on the EGF receptor amino acids 988 -998 was analyzed (42) . Furthermore, the identification of specific side chain interactions between amino acid residues of a peptide substrate DADE(p)YL and Arg 47 of PTP1B in the complex of catalytically inactive PTP1B and the peptide (43) provide additional support for the notion that PTP selectivity is determined by the primary sequence surrounding phosphorylation sites.
Accumulating evidence suggests that the biological responses triggered by the PDGF ␤-receptor and other RTKs are determined by the set of SH2 domain-containing proteins that associate with the receptor in a phosphorylation site-selective manner (reviewed in Refs. 11 and 44). Our observations suggest that the regulated activity and expression of PTPs might be a mechanism whereby receptors with various pattern of tyrosine phosphorylation and concomitant variations in the pattern of associated SH2 domain-containing proteins and signaling output could be generated. Interestingly, it was recently demonstrated that PDGF ␤-receptors from cells cultured on polylysine and fibronectin differed with regard to SHP-2 and RasGAP recruitment (45) . Further studies on PTP-dependent variations in the tyrosine phosphorylation pattern of the PDGF ␤-receptor and other RTKs in cells grown under various culture conditions, as well as in intact tissues, are therefore highly warranted.
